Objective: To determine if overnight tobacco abstinent carriers of the AG or GG (*G) vs. the AA variant of the human mu opioid receptor (OPRM1) A118G polymorphism (rs1799971) differ in [ 11 C]carfentanil binding after tobacco smoking. Methods: Twenty healthy American male smokers who abstained from tobacco overnight were genotyped and completed positron emission tomography (PET) scans with the mu opioid receptor agonist, [ 11 C]carfentanil. They smoked deniconized (denic) and average nicotine (avnic) cigarettes during the PET scans. Results: Smoking avnic cigarette decreased the binding potential (BP ND ) of [ 11 C]carfentanil in the right medial prefrontal cortex (mPfc; 6, 56, 18), left anterior medial prefrontal cortex (amPfc; −2, 46, 44), right ventral striatum (vStr; 16, 3, −10), left insula (Ins; −42, 10, −12), right hippocampus (Hippo; 18, −6, −14) and left cerebellum (Cbl; −10, −88, −34), and increased the BP ND in left amygdala (Amy; −20, 0, −22), left putamen (Put; −22, 10, −6) and left nucleus accumbens (NAcc; −10, 12, −8). In the AA allele carriers, avnic cigarette smoking significantly changed the BP ND compared to after denic smoking in most brain areas listed above. However in the *G carriers the significant BP ND changes were confirmed in only amPfc and vStr. Free mu opioid receptor availability was significantly less in the *G than the AA carriers in the Amy and NAcc. Conclusion: The present study demonstrates that BP ND changes induced by avnic smoking in OPRM1 *G carriers were blunted compared to the AA carriers. Also *G smokers had less free mu opioid receptor availability in Amy and NAcc.
Introduction
Many studies with mice have demonstrated that nicotine induces endogenous brain opioid release (Davenport et al., 1990; Dhatt et al., 1995; Isola et al., 2009 ). Furthermore C57BL/6 mice treated with large doses of nicotine result in marked tolerance to nicotine antinociception (Galeote et al., 2006) . The C57B4/6 mu opioid knockout mice also develop tolerance to nicotine antinociception more quickly. The antinociceptive actions of nicotine in rodents are not reduced by mu opioid antagonists. In humans, nicotine/tobacco smoking is not an effective analgesic. However, some brain evoked potentials due to painful laser stimuli are reduced, but C fiber effects are enhanced by tobacco smoking (Miyazaki et al., 2009 (Miyazaki et al., , 2010 .
Additional basic science studies support the importance of the opioid system, especially the mu opioid receptor (OPRM1), in drug addiction. Humanized h/mOPRM1-118 AA or h/mOPRM1-118 GG receptors (knockin) mice show different reinforcement of alcohol. The GG mice have a four-fold greater vStr/NAcc DA release to alcohol than the former (Ramchandani et al., 2011) . Also this gene is involved in opiate and cocaine addiction and treatment (Kreek et al., 2005) . Recently Zhang et al. (2015) found that GG mice self-administrated more heroin and had more brain dopamine release in response to heroin than AA mice. In mice with a lack (knockout) of the mu opioid receptor, ethanol and cocaine (Becker et al., 2002) and nicotine (Berrendero et al., 2002; Walters et al., 2005) are not rewarding. Furthermore mice with the G allele of A112G SNP (which is equivalent to human OPRM1 A118G SNP) have reduced receptor protein, less morphine induced hyperactivity, and less locomotor sensitization. Additionally, female mice have less morphine reward aversive naloxone precipitated withdrawal (Mague et al., 2009) . Ray et al. (2011) reported that smokers with the OPRM1 *G allele have reduced [ 11 C]carfentanil binding potentials (MOR BP ND ) compared to AA carriers with 0.6 mg of nicotine (nic) cigarette smoking. Reduced BP ND assumes increased endogenous opioid release and less free mu opioid receptors (activation). They also found that *G carriers had a positive association between decreased MOR BP ND and smoking 
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